Loading...
Loading...
POAI| Name | Value |
|---|---|
| Revenues | 278.7K |
| Cost of Revenue | 317.1K |
| Gross Profit | -38.4K |
| Operating Expense | 3,150.8K |
| Operating I/L | -3,189.2K |
| Other Income/Expense | 8.0K |
| Interest Income | 0.0K |
| Pretax | -3,181.3K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,181.3K |
Predictive Oncology Inc. is a knowledge-driven company specializing in personalized cancer therapies using artificial intelligence (AI) in the United States. The company operates in four segments: Helomics offers clinical testing and contract research services for patient-centric drug discovery; zPREDICTA develops organ-specific disease models for testing anticancer agents; Soluble provides services for protein stability analysis and bacterial endotoxin detection and removal; and Skyline offers the STREAMWAY System for automated infectious fluid disposal and cancer cell research media. The company generates revenue through clinical testing, contract research, disease model development, protein stability services, and medical device sales.
